Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence SHALQLNN
Primary information
sequence IDSeq_7179
Peptide sequenceSHALQLNN
CancerPDF_ID CancerPDF_ID1916, CancerPDF_ID3157, CancerPDF_ID8559, CancerPDF_ID9614,
PMID21136997,21136997,23667664,21533267
Protein NameComplement C4-B,Complement C4-A,Complement C3f,Complement C4-A
UniprotKB Entry NameCO4B_HUMAN,CO4A_HUMAN,CO3_HUMAN,CO4A_HUMAN
FluidSerum,Plasma,Serum,Serum
M/Z895.45118,895.4512,895.45,448.72
Charge1,1,1,2
Mass (in Da)NA,NA,896.98,NA
fdrNA,NA,NA,NA
Profiling TechniqueLC-MS,LC-MS,MALDI-TOF,LC-MS
Peptide Identification techniqueLC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS
Quantification TechniqueLC-ESI-MS,LC-ESI-MS,NA,Multiple Reaction Monitoring
Labelled/Label FreeLabel Free,Label Free,Label Free,Label Free
FDRNA,NA,NA,1.49
CancerPDF_ID CancerPDF_ID1916, CancerPDF_ID3157, CancerPDF_ID8559, CancerPDF_ID9614,
p-ValueNA,NA,NA,NA
SoftwareMASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT
Length8,8,8,8
Cancer TypeColorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma
DatabaseSwissProt Database,SwissProt Database,NA,Swissprot Database (57.4)
ModificationNA,NA,NA,NA
Number of Patients30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control
RegulationNA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal"
ValidationLeave One out Cross validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates
SensitivityNA,NA,NA,NA
SpecificityNA,NA,NA,NA
AccuracyNA,NA,NA,NA
Peptide AtlasNA
IEDB